Premium
Screening for depression in adult acne vulgaris patients: tools for the dermatologist
Author(s) -
Henkel Verena,
Mœhrenschlager Matthias,
Hegerl Ulrich,
Mœller HansJürgen,
Ring Johannes,
Worret WolfIngo
Publication year - 2002
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/j.1473-2165.2002.00057.x
Subject(s) - acne , medicine , depression (economics) , patient health questionnaire , psychosocial , anxiety , psychiatry , dermatology , depressive symptoms , economics , macroeconomics
Summary Background Adult dermatological out patients have a 40% prevalence of psychiatric co‐morbidity. If psychiatric co‐morbidity is unrecognized, undetected and untreated, the consequences may be fatal. Acne is the most common skin disorder of the second and third decades of life. Acne and its treatments may cause depression. Aims To identify a screening tool to identify depression in adult acne patients. Methods The literature was reviewed to identify validated screening instruments for depressive disorders. Questionnaires studied included the Hospital Anxiety and Depression Scale (HAD), the Brief Patient Health Questionnaire (B‐PHQ), the General Health Questionnaire‐12 item version (GHQ‐12), and the World Health Organization‐5 Well Being Index (WHO‐5). Results WHO‐5 performed best in terms of sensitivity (0.93 for a cut‐off score of 13) as well as taking least time to complete (2–5 min) and evaluate (0.5–2 min). Conclusions WHO‐5 can be recommended as part of a two‐step screening process for depression in acne patients. Step 1 is the WHO‐5. In the case of a positive score, step 2 is a detailed psychosocial assessment.